Healthcare Equipment and Supplies
Company Overview of Aesculap Implant Systems, Inc.
Aesculap Implant Systems, Inc. manufactures and supplies surgical instruments, implants, and supplies in North America. The company offers cardiovascular instruments, electro surgery products, general surgical instruments, laparoscopy products, sterile processing products and services, neuro instruments, and retraction systems. It also provides neurosurgery instruments, such as bipolar forceps, aneurysm clips, cranial fixation, dura substitutes, hydrocephalus shunts, neurosurgical instruments, neuroendoscopy, power systems, and spine implants; and surgical, cardiac and thoracic, maxillofacial plastics, neurosurgery, small bone, and spine power systems. In addition, the company offers wound c...
3773 Corporate Parkway
Center Valley, PA 18034
Founded in 2005
Key Executives for Aesculap Implant Systems, Inc.
President of Aesculap, Inc
Director of Orthopaedic Product Division
Director of R&D Portfolio Management & New Technologies
Compensation as of Fiscal Year 2016.
Aesculap Implant Systems, Inc. Key Developments
Aesculap Implant Systems Introduces the Modulift Vertebral Body Replacement
Jul 1 15
Aesculap Implant Systems introduced the Modulift Vertebral Body Replacement (VBR). The titanium Modulift VBR represents the latest generation in expandable cage technology by providing optimized tactile feedback, biomechanical restoration capability and ease of use. The prosthetic/bone interface was designed to address Wolff's Law with the goal of optimizing conditions for a stable fusion. Spikes and an aggressive waffle pattern achieve a high degree of initial stability, while the central packing cavity and fenestrations accommodate bone in-growth. The oval shape provides a more anatomical design for maximum surface area coverage and load transfer. Sagittal balance and biomechanical restoration are addressed with lordotic offerings of 0, 5, and 10 degrees of correction. All of these features work in concert to achieve positive bone modeling response. Surgeon ease of use is achieved with pre-loaded set screws. A low-profile dovetail attachment and self-alignment capability provide efficient, secure insertion and in-situ reattachment capability. This unique connection design allows for a minimum profile inserter which optimizes visualization during the critical expansion process. Also, the trial, insertion and expansion instrumentation occupy only one tray.
Aesculap Implant Systems, LLC Receives FDA Approval for the activL® Artificial Disc for One-Level Lumbar Use
Jun 15 15
Aesculap Implant Systems, LLC announced that it has received a letter of approval from the U.S. Food and Drug Administration (FDA) allowing the commercial sale of the activL Artificial Disc, for the treatment of one-level lumbar degenerative disc disease. The activL Artificial Disc features cobalt chromium endplates which affix to the patient's vertebrae with bone-sparing spikes for initial stabilization. It is the first lumbar artificial disc with a mobile ultrahigh molecular weight polyethylene core that supports both controlled translational and rotational movement similar to the movement of the healthy lumbar spine. It offers the widest range of footprints and heights, including an 8.5 mm design, which is the lowest height construct available on the market. In the Investigational Device Exemption (IDE) trial, the activL Artificial Disc demonstrated non-inferiority in overall trial success compared to conventional total disc replacement designs. In the analysis of primary outcomes from the IDE trial, the activL Artificial Disc was non-inferior to the control devices tested but also had a greater overall success rate (p < 0.0001). During their respective IDE trials, these conventional disc designs were compared to fusion surgery. The Aesculap Implant Systems activL Artificial Disc is indicated for reconstruction of the disc at one level (L4-L5 or L5-S1) following single-level discectomy in skeletally mature patients with symptomatic degenerative disc disease with no more than Grade I spondylolisthesis at the involved level. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history, physical examination, and radiographic studies. The activL® Artificial Disc is implanted using an anterior retroperitoneal approach. Patients receiving the activL® Artificial Disc should have failed at least six months of nonoperative treatment prior to implantation of the device.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|